Researchers found that artificially increasing the levels of a molecule called AST (antisense transcript), an antisense RNA ...

Ionis Pharmaceuticals (NASDAQ:IONS) reported Q2 2025 GAAP revenue and non-GAAP earnings per share that exceeded analyst expectations by wide margins. The profit surge in Q2 2025 included a ...

The Oligonucleotide Therapeutics Society (OTS) is pleased to announce the 21st Annual OTS Meeting, scheduled for October ...

Gene therapy appears to be a promising approach for a subset of genetic deafness, although challenges remain with development ...

A team led by Prof. CHEN Lingling from the Center for Excellence in Molecular Cell Science of the Chinese Academy of Sciences revealed a spatiotemporal separation in the processing of distinct rRNA ...

WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver ...

Nucleic acid therapies offer targeted treatment for genetic diseases, but delivery remains a key hurdle. Explore how advances ...

We need a dedicated framework that clarifies the rules, requirements and incentives for those building personalized ...

Since starting operations in North Carolina 30 years ago, Biogen has spent approximately $10 billion to bolster its ...

Data supports further evaluation of investigational antisense OT‑101 (trabedersen) as a TGFB2‑targeted approach in pancreatic ductal adenocarcinoma.

4 analysts have shared their evaluations of WAVE Life Sciences WVE -3.57% + Free Alerts during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a ...